Latest industry research report on: Global Cancer Genome Sequencing Market 2016: Industry Research, Size, Shares, Key Trends, Demand, Growth to 2022
Cancer genome sequencing refers to a method used to identify the complete DNA or RNA sequence of cancer cells based on the sequencing of a single, homogeneous or heterogeneous group of tumor cells. It is a laboratory technique that characterizes DNA or RNA sequences of primary tumor tissue, the tumor micro environment (such as stromal / fibroblast cells), adjacent or distal normal tissue, or metastatic tumor sites. This technique generates information related to identification of nucleotide bases (DNA or RNA), mutation status, copy number and sequence variants, as well as structural variations including fusion genes and chromosomal translocations. This technique has proved to be a breakthrough in the fight against cancer as it assists in individualization of treatment.
Development of new methods and exponential decrease in genome sequencing cost are fueling the market growth. Global cancer genome sequencing market is expected grow with a healthy CAGR due to technological advances and entry of new market players. Agilent Technologies, GE Healthcare Life Sciences, Johnson & Johnson, LI-COR Biosciences (Lincoln, NE), Abbott Laboratories, Beckman Coulter (Fullerton, CA), Bayer Corporation, Hamilton Thorne Biosciences, Integrated DNA Technologies, Microchip Biotechnologies, Myriad Genetics, Commonwealth Biotechnologies, ZS Genetics, and Pacific Biosciences are some of the key players of this market.
Get Free Sample Report Of Cancer Genome Sequencing Market :http://www.custommarketinsights.com/world-cancer-genome-sequencing-market-/102629#cs_tabs_request_for_sample
The global cancer genome sequencing market is segmented on the basis of technology and geography. The currently technologies used include second generation and third generation platforms. Second generation technology platforms include SOLiD sequencing (by ABI), Pyro-sequencing (by Roche) and Bridge amplification sequencing technology (by Illumina). Third generation technology platform includes Single Molecule Real Time (SMRT) sequencing (by Pacific Biosciences), Ion semiconductor sequencing, Nanopore sequencing (by Oxford) and fluorescent resonant energy transfer (FRET) sequencing (by VisiGen biotechnologies).
Geographically, the global cancer genome sequencing market is segmented into North America, Europe, Asia-Pacific and LAMEA. North America dominates the global cancer genome sequencing market due to availability of advanced technologies and a skilled workforce. This market is driven by whole genome sequencing coupled with bioinformatics based sequencing technologies which provide personalized treatments for cancer.
Have Any Query? Ask Our Expert @http://www.custommarketinsights.com/world-cancer-genome-sequencing-market-/102629#cs_tabs_enquiry_for_buying
This report offers the following benefits in particular:
MARKET BY TECHNOLOGY
MARKET BY GEOGRAPHY
About Custom Market Insights:
Market Research supports various market segment programs; provides trusted technical services to the marketing departments. It carries out accurate market share and forecast analysis services for a range of commercial and government customers globally. These are all vital market research support solutions requiring trust and integrity.
Custom Market Insights is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive.
What makes us different from our competitors?
Compared to our competitors, our offerings include, but are not limited to market research services on latest industry trends, customized study at reasonable price, and database bigger than our competitors and provide more relevant results to fit your needs.
3422 SW 15 Street, Suit #8138,
Deerfield Beach, Florida 33442,
GMT Tel: +49-322 210 92714
USA/Canada Toll Free No. 1-855-465-4651